Table 1—

Demographics and results

Baseline
3 months
CHMGComparisonPCHMGComparisonP
n2423NS
Age (years)45.8 ± 13.244.3 ± 13.40.703
Duration (years)27.2 ± 16.624.0 ± 15.80.513
Sex (male/female)11/1310/130.871
BMI (kg/m2)26.1 ± 4.126.9 ± 4.80.565
Treatment
    MDI18160.677
    CSII670.677
A1C (%)7.43 ± 1.0*7.39 ± 1.00.8967.06 ± 0.8*7.73 ± 1.40.039
Target A1C
    <7.5%14 of 2413 of 230.90020 of 2412 of 230.023
    <7.0%7 of 246 of 230.81412 of 246 of 230.211
    <6.5%4 of 244 of 231.0004 of 243 of 231.000
Insulin dose51.9 ± 31.445.7 ± 28.60.41350.1 ± 31.449.0 ± 33.40.310
Glucose target ranges (%)
    WTR42.6 ± 19.5NANA49.1 ± 16.7NA0.0353§
    ATR53.2 ± 20.4NANA47.6 ± 17.0NA0.0355§
    BTR4.2 ± 3.5NANA3.4 ± 6.7NA0.638§
  • Data are means ± SD or n unless otherwise indicated.

  • *

    * There was a significant decrease (P = 0.047) in A1C in the CHMG group from baseline to 3 months.

  • There was no significant change in total insulin dose in the CHMG or comparison group from baseline to 3 months.

  • WTR glycemia was defined as 60–150 mg/dl (3.3–8.3 mmol/l).

  • §

    § These P values represent differences in glucose target ranges from baseline to 3 months in the CHMG group using mixed-model repeated-measures analysis. CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection; NA, not applicable; NS, not significant.